O	0	4	Long
O	4	5	-
O	5	9	term
O	10	16	follow
O	16	17	-
O	17	19	up
O	20	22	of
O	23	24	a
O	25	35	randomised
O	36	41	trial
O	42	50	designed
O	51	53	to
O	54	63	determine
O	64	67	the
O	68	72	need
O	73	76	for
B-intervention	77	88	irradiation
I-intervention	89	98	following
I-intervention	99	111	conservative
I-intervention	112	119	surgery
O	120	123	for
O	124	127	the
O	128	137	treatment
O	138	140	of
O	141	149	invasive
O	150	156	breast
O	157	163	cancer
O	163	164	.

B-total-participants	165	169	Four
I-total-participants	170	177	hundred
O	178	189	consecutive
O	190	198	patients
O	199	203	aged
B-age	204	209	under
I-age	210	212	70
I-age	213	218	years
B-eligibility	219	228	diagnosed
I-eligibility	229	233	with
I-eligibility	234	235	a
I-eligibility	236	244	clinical
I-eligibility	245	247	T1
I-eligibility	248	250	or
I-eligibility	251	253	T2
I-eligibility	254	260	breast
I-eligibility	261	267	cancer
O	268	272	were
O	273	283	randomised
O	284	286	to
O	287	294	receive
B-intervention	295	299	post
I-intervention	299	300	-
I-intervention	300	309	operative
I-intervention	310	322	radiotherapy
O	323	324	(
O	324	325	n
O	326	327	=
B-intervention	328	331	208
O	331	332	)
O	333	335	or
B-control	336	339	not
O	340	341	(
O	341	342	n
O	343	344	=
B-control-participants	345	348	192
O	348	349	)
O	349	350	,
O	351	354	and
O	355	364	monitored
O	365	367	to
O	368	374	record
O	375	378	all
O	379	384	local
O	385	396	recurrences
O	396	397	,
O	398	405	distant
O	406	417	recurrences
O	418	421	and
O	422	428	deaths
O	429	432	for
O	433	435	up
O	436	438	to
O	439	441	20
O	442	447	years
O	448	449	(
O	449	455	median
O	456	458	13
O	458	459	.
O	459	460	7
O	461	466	years
O	466	467	)
O	467	468	.

O	469	472	All
O	473	481	patients
O	482	486	were
O	487	494	treated
O	495	497	by
O	498	502	wide
O	503	508	local
O	509	517	excision
O	518	521	and
O	522	530	adjuvant
O	531	538	therapy
O	539	540	[
O	540	548	estrogen
O	549	557	receptor
O	558	559	(
O	559	561	ER
O	561	562	)
O	563	571	positive
O	571	572	:
O	573	582	tamoxifen
O	582	583	;
O	584	586	ER
O	587	595	negative
O	595	596	:
O	597	600	CMF
O	601	613	chemotherapy
O	613	614	]
O	614	615	.

O	616	622	Kaplan
O	622	623	-
O	623	628	Meier
O	629	632	and
O	633	636	log
O	636	637	-
O	637	641	rank
O	642	646	test
O	647	654	methods
O	655	659	were
O	660	664	used
O	665	667	to
O	668	676	estimate
O	677	680	and
O	681	688	compare
O	689	697	survival
O	698	701	and
O	702	712	recurrence
O	712	713	.

O	714	717	The
O	718	720	20
O	720	721	-
O	721	725	year
O	726	732	Kaplan
O	732	733	-
O	733	738	Meier
O	739	744	rates
O	745	748	for
B-outcome	749	754	local
I-outcome	755	761	breast
I-outcome	762	772	recurrence
O	773	777	were
B-iv-bin-percent	778	780	28
I-iv-bin-percent	780	781	.
I-iv-bin-percent	781	782	6
I-iv-bin-percent	782	783	%
O	784	785	[
O	785	787	95
O	787	788	%
O	789	799	confidence
O	800	808	interval
O	809	810	(
O	810	812	CI
O	812	813	)
O	814	816	19
O	816	817	.
O	817	818	6
O	818	819	%
O	820	822	to
O	823	825	37
O	825	826	.
O	826	827	6
O	827	828	%
O	828	829	]
O	830	833	for
O	834	846	radiotherapy
O	847	850	and
B-cv-bin-percent	851	853	49
I-cv-bin-percent	853	854	.
I-cv-bin-percent	854	855	8
I-cv-bin-percent	855	856	%
O	857	858	(
O	858	860	95
O	860	861	%
O	862	864	CI
O	865	867	40
O	867	868	.
O	868	869	8
O	869	870	%
O	871	873	to
O	874	876	58
O	876	877	.
O	877	878	9
O	878	879	%
O	879	880	)
O	880	881	.

O	882	887	There
O	888	891	was
O	892	894	no
O	895	906	significant
O	907	917	difference
O	918	925	between
O	926	929	the
O	930	933	two
O	934	940	groups
O	941	945	with
O	946	952	regard
O	953	955	to
B-outcome	956	963	disease
I-outcome	963	964	-
I-outcome	964	968	free
I-outcome	969	971	or
I-outcome	972	979	overall
I-outcome	980	988	survival
O	988	989	.

O	990	993	The
B-outcome	994	1000	hazard
I-outcome	1001	1006	ratio
I-outcome	1007	1010	for
I-outcome	1011	1016	death
O	1017	1022	among
O	1023	1028	women
O	1029	1032	who
O	1033	1041	received
O	1042	1051	radiation
O	1051	1052	,
O	1053	1055	as
O	1056	1064	compared
O	1065	1069	with
O	1070	1075	those
O	1076	1080	that
O	1081	1084	did
O	1085	1088	not
O	1088	1089	,
O	1090	1093	was
O	1094	1095	0
O	1095	1096	.
O	1096	1098	91
O	1099	1100	(
O	1100	1102	95
O	1102	1103	%
O	1104	1106	CI
O	1107	1108	0
O	1108	1109	.
O	1109	1111	64
O	1111	1112	-
O	1112	1113	1
O	1113	1114	.
O	1114	1116	28
O	1116	1117	;
O	1118	1119	P
O	1120	1121	=
O	1122	1123	0
O	1123	1124	.
O	1124	1126	59
O	1126	1127	)
O	1127	1128	.

O	1129	1138	Therefore
O	1138	1139	,
O	1140	1144	post
O	1144	1145	-
O	1145	1154	operative
O	1155	1167	radiotherapy
O	1168	1176	produced
O	1177	1178	a
O	1179	1184	clear
O	1184	1185	-
O	1185	1188	cut
O	1189	1198	reduction
O	1199	1201	in
B-outcome	1202	1214	locoregional
I-outcome	1215	1225	recurrence
O	1226	1227	0
O	1227	1228	.
O	1228	1230	45
O	1231	1232	(
O	1232	1233	0
O	1233	1234	.
O	1234	1236	31
O	1236	1237	-
O	1237	1238	0
O	1238	1239	.
O	1239	1241	64
O	1241	1242	;
O	1243	1244	P
O	1245	1246	=
O	1247	1248	0
O	1248	1249	.
O	1249	1253	0001
O	1253	1254	)
O	1254	1255	,
O	1256	1259	but
O	1260	1263	did
O	1264	1267	not
O	1268	1277	influence
O	1278	1281	the
B-outcome	1282	1291	incidence
I-outcome	1292	1294	of
I-outcome	1295	1302	distant
I-outcome	1303	1313	metastases
O	1314	1316	or
B-outcome	1317	1321	time
I-outcome	1322	1324	of
I-outcome	1325	1330	death
O	1330	1331	.

O	1332	1339	However
O	1339	1340	,
O	1341	1343	of
O	1344	1347	the
O	1348	1351	119
O	1352	1360	patients
O	1361	1364	who
O	1365	1368	had
O	1369	1370	a
O	1371	1376	local
O	1377	1387	recurrence
O	1387	1388	,
O	1389	1391	51
O	1392	1393	(
O	1393	1395	42
O	1395	1396	.
O	1396	1397	8
O	1397	1398	%
O	1398	1399	)
O	1400	1403	had
O	1404	1405	a
B-outcome	1406	1413	distant
I-outcome	1414	1424	recurrence
O	1424	1425	,
O	1426	1433	whereas
O	1434	1436	of
O	1437	1440	the
O	1441	1444	281
O	1445	1452	without
O	1453	1458	local
O	1459	1469	recurrence
O	1470	1474	only
O	1475	1477	59
O	1478	1479	(
O	1479	1481	21
O	1481	1482	%
O	1482	1483	)
O	1484	1488	ever
O	1489	1492	had
O	1493	1494	a
B-outcome	1495	1502	distant
I-outcome	1503	1513	recurrence
O	1513	1514	.

O	1515	1516	A
O	1517	1520	Cox
O	1520	1521	'
O	1521	1522	s
O	1523	1533	regression
O	1534	1542	analysis
O	1543	1547	with
O	1548	1553	local
O	1554	1564	recurrence
O	1565	1567	as
O	1568	1569	a
O	1570	1574	time
O	1574	1575	-
O	1575	1584	dependent
O	1585	1593	variable
O	1594	1600	showed
O	1601	1602	a
O	1603	1607	risk
O	1608	1613	ratio
O	1614	1616	of
O	1617	1618	5
O	1618	1619	.
O	1619	1621	28
O	1622	1623	(
O	1623	1624	P
O	1625	1626	<
O	1627	1628	0
O	1628	1629	.
O	1629	1633	0001
O	1633	1634	)
O	1634	1635	.

O	1636	1640	This
O	1641	1647	strong
O	1648	1660	relationship
O	1661	1663	is
O	1664	1673	dependent
O	1674	1676	on
O	1677	1680	the
O	1681	1690	intensity
O	1691	1693	of
O	1694	1698	post
O	1698	1699	-
O	1699	1708	treatment
O	1709	1715	follow
O	1715	1716	-
O	1716	1718	up
O	1719	1722	and
O	1723	1736	investigation
O	1736	1737	.
